NGS testing in clinical practice - what to expect
“Using the Devyser Thalassemia kit, we can reduce both response time and costs. One single assay provides all the information we need.”
- Dr. Veysel Sabri Hancer, Professor, Istinye University, Genetic Diseases Diagnostic Centre, Istanbul, Turkey
An estimated 5.2 percent of individuals worldwide carry a genetic mutation that causes thalassemia. Research indicates that 1.1 percent of couples worldwide are at risk of having children with a hemoglobin disorder, and that 2.7 children out of 1,000 conceptions are affected.
Family history and geographic origin can be significant risk factors. Thalassemia primarily affects people with Mediterranean, South Asian, Southeast Asian, and Middle Eastern ancestry.
Diagnostic DNA tests can identify the genetic mutation associated with thalassemia. Detection often takes place during pregnancy or soon after birth. Some countries offer routine screening for thalassemia to all pregnant women.
Tests can also be performed at any age to check for thalassemia or to see if an individual is a carrier.
Our one-tube test solution significantly reduces lab turnaround time and simplifies the clinical workflow for genetic testing of thalassemia in a single assay.
By eliminating the need for multiple parallel testing protocols, we have successfully replaced traditional methods with one test to meet growing laboratory demand for rapid, convenient screening.
Results in under five hours
The unique end-to-end procedure makes it possible to go from DNA to result in less than five hours, with under 45 minutes of handling time. Data analysis is swift and straightforward thanks to dedicated software.
The fast and simple NGS workflow is suitable for any lab, whether you are running advanced genetic testing or large-scale mutation screening.
Fast and effective test data analysis is crucial to achieving accurate outcomes and efficient workflows.
Dedicated software in our products makes analyzing test results quick, easy and trouble-free. For lab personnel, this means a streamlined end-to-end process with unmatched reliability and transparency.Find out more
News | December 1, 2022
New chimerism software for your improved workflow -speed, usability, and customizable reports
Time is precious. Every minute, every second that we can simplify your lab’s workflow shortens the...Find out more
News | November 17, 2022NGS for thalassemia genetic testing – insights from a customer implementation journey
News | November 10, 2022Devyser Diagnostics AB publishes Interim Report for the period, January to September 2022
News | November 9, 2022Devyser strengthens its presence on the US market - establishes proprietary CLIA lab
Thalassemia is typically caused by sequence variants in the HBA1, HBA2 or HBB genes. The common...
Thalassemia is an inherited blood disorder with a worldwide prevalence of nearly 300,000 per year....
Alpha- and beta-thalassemia are distinct hematologic disorders caused by a defect in globin chain...